

Jos A. Carrin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1048885/jose-a-carrion-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88
papers

2,665
citations

22
h-index

50
g-index

133
ext. papers

3,291
ext. citations

4.1
avg. IF

4.33
L-index

#	Paper	IF	Citations
88	Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial.. <i>Scientific Reports</i> , 2022 , 12, 316	4.9	3
87	On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty.. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	2
86	Multi-organ Involvement in Non-pulmonary Sarcoidosis.. <i>Reumatologia Clínica (English Edition)</i> , 2022 , 18, 309-311	0.1	
85	Author's reply: Nucleo(s)ide analogue withdrawal in chronic hepatitis B virus infection. Beyond the HBsAg loss.. <i>Digestive and Liver Disease</i> , 2022 ,	3.3	
84	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 519-530	6.1	2
83	Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 32, 214-222	2.2	0
82	Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1319-1324	3.4	2
81	Multi-organ Involvement in Non-pulmonary Sarcoidosis. <i>Reumatologia Clínica</i> , 2021 ,	0.9	1
80	Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. <i>Liver International</i> , 2021 , 41, 2733-2746	7.9	0
79	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 52, 500-512	6.1	3
78	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020 , 72, 1112-1121	13.4	22
77	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1570-1578	4	7
76	Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. <i>World Journal of Hepatology</i> , 2020 , 12, 1076-1088	3.4	3
75	Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. <i>Journal of Gastroenterology</i> , 2020 , 55, 205-216	6.9	12
74	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
73	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019 , 153, 169-177	0.3	
72	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019 , 70, 874-884	13.4	44

71	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019 , 71, 666-672	13.4	35
70	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica</i> , 2019 , 153, 169-177	1	7
69	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019 , 70, e493-e494	13.4	4
68	PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis. <i>Journal of Hepatology</i> , 2019 , 70, e113-e114	13.4	3
67	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfecting with human immunodeficiency virus-1 in Spain. <i>PLoS ONE</i> , 2019 , 14, e0225061	3.7	3
66	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 657-676	0.9	3
65	1058 Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019 , 114, S599-S600 ^{0.7}		
64	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425
63	Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. <i>Liver International</i> , 2019 , 39, 90-97	7.9	4
62	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 55-64	3.4	16
61	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 811-817	3.4	19
60	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 328-349	0.9	30
59	Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 1100-1107	4	5
58	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 597-608	0.9	10
57	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018 , 155, 1120-1127.e4	13.3	47
56	Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis. <i>Journal of Hepatology</i> , 2018 , 68, S20-S21	13.4	3
55	Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1156-1161	6.1	39
54	Impact of anthropometric features on the applicability and accuracy of FibroScan (M and XL) in overweight/obese patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017 , 32, 1746-1753 ⁴		22

53	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. <i>Hepatology</i> , 2017 , 65, 1810-1822	11.2	64
52	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
51	Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy-authors'Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 1559-1560	6.1	1
50	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1400-1409	0.7	20
49	Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 304-311	3.4	33
48	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 226-237	3.4	17
47	Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2850-2856	5.1	8
46	Hepatitis B Reactivation or Hepatitis C Exacerbation in Patients with Hematological Malignancies. <i>Annals of Hepatology</i> , 2017 , 16, 179-181	3.1	1
45	Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017 , 16, 312-317	3.1	3
44	Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. <i>PLoS ONE</i> , 2017 , 12, e0188303	3.7	7
43	Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. <i>Revista Española De Sanidad Penitenciaria</i> , 2017 , 19, 87-97	0.4	9
42	Effectiveness and Safety of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Patients with Genotype 1 Chronic Hepatitis C Virus Infection: Results from the Spanish Real World Cohort. <i>Journal of Hepatology</i> , 2016 , 64, S218-S219	13.4	7
41	Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 364-74	6.1	12
40	Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. <i>PLoS ONE</i> , 2016 , 11, e0164883	3.7	6
39	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. <i>PLoS ONE</i> , 2016 , 11, e0166631	3.7	4
38	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , 2016 , 29, 698-706	3	4
37	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016 , 64, S133	13.4	8
36	Clinical Value of Thyrotropin Receptor Antibodies for the Differential Diagnosis of Interferon Induced Thyroiditis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016 , 124, 39-44	2.3	0

35	Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort. <i>Journal of Hepatology</i> , 2016 , 64, S217-S218	13.4	7
34	Quantification of HBsAg (HBsAg-Q) in HBeAg-Negative Patients Receiving Nucleos(T)ide Analogues to Predict the Loss of HBsAg. <i>Journal of Hepatology</i> , 2016 , 64, S379	13.4	
33	Platelet Count and Liver Stiffness Measurement to Exclude High-Risk Gastroesophageal Varices in Patients with HCV-Cirrhosis. A Multicentric Study. <i>Journal of Hepatology</i> , 2016 , 64, S273	13.4	2
32	Predictive model of mortality in patients with spontaneous bacterial peritonitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 629-37	6.1	12
31	Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. <i>Liver International</i> , 2015 , 35, 1557-65	7.9	5
30	Applicability and accuracy improvement of transient elastography using the M and XL probes by experienced operators. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 297-306	3.4	17
29	P0190 : Predictive model of mortality in cirrhotic patients with high risk spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2015 , 62, S375	13.4	2
28	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5421-6	5.6	5
27	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015 , 62, 311-6	13.4	11
26	Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. <i>American Journal of Transplantation</i> , 2014 , 14, 375-83	8.7	39
25	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , 2013 , 48, 762-9	6.9	17
24	A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 926-33	13.4	28
23	155 EFFICACY AND SAFETY OF STANDARD ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION (LT). <i>Journal of Hepatology</i> , 2013 , 58, S69-S70	13.4	2
22	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. <i>Liver Transplantation</i> , 2013 , 19, 450-6	4.5	7
21	Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011 , 23, 942-7	2.2	5
20	Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. <i>American Journal of Transplantation</i> , 2011 , 11, 1051-7	8.7	71
19	Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study. <i>Transplantation</i> , 2011 , 92, 334-40	1.8	31
18	Severe acute hepatitis in the dress syndrome: Report of two cases. <i>Annals of Hepatology</i> , 2010 , 9, 198-203	3.1	24

17	Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. <i>Gastroenterology</i> , 2010 , 138, 147-58.e1	13.3	56
16	Replantation in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2010 , 53, 962-70	13.4	52
15	Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. <i>Hepatology</i> , 2010 , 51, 23-34	11.2	103
14	Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. <i>Journal of General Virology</i> , 2010 , 91, 1183-8	4.9	31
13	Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. <i>American Journal of Transplantation</i> , 2009 , 9, 1591-601	8.7	45
12	Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. <i>Journal of Hepatology</i> , 2009 , 50, 719-28	13.4	167
11	Antiviral therapy in HCV-infected cirrhotic patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2009 , 51, 960-962	13.4	0
10	MR elastography to assess liver fibrosis. <i>Radiology</i> , 2008 , 247, 591; author reply 591-2	20.5	9
9	Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. <i>Gastroenterology</i> , 2007 , 132, 1746-56	13.3	299
8	Noninvasive tests in the post-liver transplantation setting. <i>Liver Transplantation</i> , 2007 , 13, 628-629	4.5	1
7	Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. <i>American Journal of Transplantation</i> , 2007 , 7, 2172-9	8.7	8
6	[87] EFFICACY OF ANTIVIRAL THERAPY ON DISEASE PROGRESSION IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY. <i>Journal of Hepatology</i> , 2007 , 46, S39-S40	13.4	3
5	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006 , 43, 492-9	11.2	238
4	Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 1791-8	4.5	315
3	150 Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2006 , 44, S64	13.4	6
2	Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 544-51	3.4	13
1	Large spontaneous splenorenal shunt as a cause of chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 2004 , 40, 868	13.4	7